Log In
Print
BCIQ
Print
Print this Print this
 

Valdoxan, agomelatine (Thymanax) (AGO178)

  Manage Alerts
Collapse Summary General Information
Company Servier
DescriptionMelatonin MT1 and MT2 receptor agonist and serotonin (5-HT2C) receptor antagonist
Molecular Target Melatonin MT1 receptor ; Melatonin MT2 receptor
Mechanism of ActionSerotonin (5-HT2C) receptor antagonist; Melatonin MT2 receptor agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDepression
Indication DetailsTreat major depressive disorder (MDD); Treat major depressive episodes
Regulatory Designation

Partner

Novartis AG


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today